France considers participation in Sanofi subsidiary Opella

The French state is showing interest in a possible involvement in Sanofi's Opella division to allay concerns about potential job cuts. Sanofi plans to sell 50% of Opella to the American investment company Clayton Dubilier & Rice, causing unease among unions and the opposition. French Finance Minister Antoine Armand announced in Parliament that the government is considering several options for Opella, including a seat on the company's supervisory board. The goal is to preserve France's economic sovereignty and not jeopardize the industrial strategy of recent years. Armand emphasized that all options are on the table and nothing is being excluded. Additionally, the government is demanding from Sanofi the guarantee that the production of the well-known painkiller Doliprane will continue to take place in France. This is a central component of the sovereign industrial policy that France has developed.